Association of blood and marrow chimerism status at day 28 with subsequent rejection and acute graft-versus-host disease
| Cell fraction . | Percent donor chimerism as a continuous (0-100%) variable . | |||||
|---|---|---|---|---|---|---|
| Rejection . | GVHD . | |||||
| OR5-150 . | 95% CI . | Pvalue5-151 . | OR5-150 . | 95% CI . | Pvalue5-151 . | |
| Marrow | 0.4 | 0.2-0.8 | .009 | 0.7 | 0.3-1.6 | .42 |
| PB neutrophils | 0.4 | 0.2-0.7 | .004 | 1.2 | 0.6-2.5 | .62 |
| PB T cells | 0.1 | 0.04-0.5 | .003 | 2.6 | 1.1-6.4 | .03 |
| Cell fraction . | Percent donor chimerism as a continuous (0-100%) variable . | |||||
|---|---|---|---|---|---|---|
| Rejection . | GVHD . | |||||
| OR5-150 . | 95% CI . | Pvalue5-151 . | OR5-150 . | 95% CI . | Pvalue5-151 . | |
| Marrow | 0.4 | 0.2-0.8 | .009 | 0.7 | 0.3-1.6 | .42 |
| PB neutrophils | 0.4 | 0.2-0.7 | .004 | 1.2 | 0.6-2.5 | .62 |
| PB T cells | 0.1 | 0.04-0.5 | .003 | 2.6 | 1.1-6.4 | .03 |
Analysis of GVHD restricted to 35 patients with sustained engraftment and without GVHD before day 28. Patient UL627 was excluded from analysis because of lack of DNA polymorphism.
GVHD indicates graft-versus-host disease; CI, confidence interval; OR, odds ratio; PB, peripheral blood.
OR presented as an increase of 25% in donor chimerism. For example, the odds of rejection among patients with 50% donor T-cell chimerism are 0.4 times the odds of rejection among patients with 25% donor T-cell chimerism.
P value obtained from logistic regression, Wald test.